Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation

There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardona‐Gonzalez, Maria G., Goldman, Jason D., Narayan, Lawrence, Brainard, Diana M., Kowdley, Kris V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287482/
https://www.ncbi.nlm.nih.gov/pubmed/30556034
http://dx.doi.org/10.1002/hep4.1280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287482/
https://www.ncbi.nlm.nih.gov/pubmed/30556034
http://dx.doi.org/10.1002/hep4.1280

Ejemplares similares